Structured products on retail platforms - risk or reward?

clock

Structured products are rarely used on platforms in the UK but Jasper Thomas, investment funds manager at Aviva Pensions & Investments, says there are more reasons than ever for financial advisers to be considering them in a post-RDR world.

It continues to surprise me how little we see structured products used on wrap platforms in the UK. Even Aviva’s rapidly growing platform has a very small proportion of assets under administration (AuA) in structured products or exchange-traded securities. But, perhaps, it’s time for the market to change its perception of structured products and it is here we see significant opportunities. An overlooked category From a market perspective, given the wealth of geographies, sectors, asset types, risk tolerances and wrappers which can be catered for in structured products, this fundamen...

To continue reading this article...

Join Investment Week for free

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

More on Specialist

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

‘Dedicated specialists’

James Baxter-Derrington
clock 06 April 2023 • 4 min read
European private equity yet to spend €270bn worth of capital

European private equity yet to spend €270bn worth of capital

Deployment of capital expected

Kathleen Gallagher
clock 04 January 2023 • 1 min read
Early-stage biopharma: An opportunity for strategic investment

Early-stage biopharma: An opportunity for strategic investment

Disproportionately smaller investment

Ali H. Munawar
clock 10 August 2022 • 4 min read
Trustpilot